Remission induction therapy: The more intensive the better?

Cancer Chemotherapy and Pharmacology

Volumn 48, Issue SUPPL. 1, 2001, Pages

  Büchner, Thomas ^a,b   Hiddemann, Wolfgang ^a   Berdel, Wolfgang ^a   Wörmann, Bernhard ^a   Löffler, Helmut ^a   Schoch, Claudia ^a   Haferlach, Torsten ^a   Ludwig, Wolf Dieter ^a   Maschmeyer, Georg ^a   Staib, Peter ^a   Andreesen, Reinhard ^a   Balleisen, Leopold ^a   Haase, Detlef ^a   Eimermacher, Hartmut ^a   Aul, Carlo ^a   Rasche, Herbert ^a   Uhlig, Jens ^a   Grüneisen, Andreas ^a   Reis, Hans Edgar ^a   Hartlapp, Joachim ^a   Hirschmann, Wolf Dietrich ^a   Weh, Hans Josef ^a   Pielken, Hermann Josef ^a   Gassmann, Winfried ^a   Sauerland, Maria Cristina ^a   Heinecke, Achim ^a   more..

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Acute myeloid leukemia; Double induction; High dose AraC

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAT PROTOCOL 1; DAUNORUBICIN; TIOGUANINE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; HUMAN; MIDDLE AGED; MYELOID LEUKEMIA; REMISSION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; CYTARABINE; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKEMIA, MYELOID; MIDDLE AGED; REMISSION INDUCTION; THIOGUANINE;

EID: 0001907103     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100305     Document Type: Article

References (15)

1. Bishop JF, Matthews JP, Young GA, Szer J, Gillet A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, Cobcroft R, Herrmann R, Van Der Weyden M, Lowenthal RM, Page F, Garson OM, Juneja S (1996) A randomized study of high-dose cytarabine induction in acute myeloid leukemia. Blood 87:1710
2. Büchner T, Urbanitz D, Hiddemann W, Ludwig WD, Aul HC, Vaupel HA, Kuse R, Zeile G, Nowrousian MR, König HJ, Walter M, Wendt FC, Sodomann H, Hossfeld DK, von Paleske A, Löffler H, Gassmann W, Hellriegel KP, Fülle HH, Lunscken C, Emmerich B, Pralle H, Pees HW, Pfreundschuh M, Bartels H, Koeppen KM, Schwerdtfeger R, Donhuijsen-Ant R, Mainzer K, Bonfert B, Köppler H, Zurborn KH, Ranft K, Thiel E, Heinecke A (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 3:1583
3. Büchner T, Hiddemann W, Löffler G, Gassmann W, Maschmeier G, Heit W, Hossfeld D, Weh H, Ludwig WD, Thiel E, Nowrousian M, Aul C, Lengfelder E, Lathan B, Mainzer K, Urbanitz D, Emmerich B, Middelhoff G, Donhuijsen-Ant HR, Hellriegel HP, Heinecke A (1991) Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML Cooperative Group. Semin Hematol 28 [Suppl 4]:76
4. Büchner T, Hiddemann W, Wörmann B, Löffler H, Gassmann W, Haferlach T, Fonatch C, Haase D, Schoch C, Hossfeld D, Lengfelder E, Aul C, Heyll A, Maschmeyer G, Ludwig WD, Sauerland MC, Heinecke A (1999) Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine. A randomized trial by the German AML Cooperative Group. Blood 93:4116
5. Büchner T, Hiddemann W, Wörmann B, Löffler H, Gassmann W, Haferlach T, Schoch C, Staib P, Lengfelder E, Aul C., Heyll A, Ludwig WD, Maschmeier G, Grüneisen A, Balleisen L, Rasche H, Eimermacher H, Karow J, Eggeling B, Schott G, Reis E, Sauerland MC, Heinecke A (1999) One single course of sequential high-dose AraC/mitoxantrone (S-HAM) has the same long-term effect as three years of maintenance in AML patients after TAD-HAM double induction. Randomized trial by the German AMLCG. Blood 94 [Suppl 1]:383a
6. Büchner T, Hiddemann W, Wörmann B, Löffler H, Haferlach T, Fonatsch C, Haase D, Schoch E, Lengfelder E, Aul E, Heyll A, Maschmeier G, Ludwig WD, Sauerland MC, Heinecke A, for the AMLCG (1999) Improvement of prognosis in poor prognosis AML by intensified induction chemotherapy. Proc Am Soc Clin Oncol 18:6a
7. Büchner T, Hiddemann W, Schoch C, Haferlach T, Sauerland MC, Heinecke A (2000) Acute myeloid leukemia (AML): treatment of the older patient. In: Burnett A (ed) Bailliere's clinical haematology (in press)
8. Burnett AK, Goldstone AH, Stevens R, Hann I, Rees JK, Gray RG, Wheatley K (1998) Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet 351:700
9. Hamblin TJ (1992) The treatment of acute myeloid leukemia preceded by the myelodysplastic syndrome. Leuk Res 16:4101
10. +/efflux cases. Blood 86:2329
11. Leith CP, Kopecky KJ, Godwin J, McConnel T, Slovak ML, Chen IM, Head DR, Appelbaum FR, Willman CL (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biological subgroups with remarkably distinct response to standard chemotherapy. A Southwest Oncology Group Study. Blood 89:3323
12. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E (1994) Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896
13. Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, Preisler HD, Nawabi IW, Prager D, Carey RW, Cooper MR, Haurani F, Hutchsion JL, Silver RT, Falkson G, Wiernik P, Hoagland HC, Bloodfield CD, James GW, Gottlieb A, Ramanan SV, Blom J, Nissen NI, Bank A, Ellison RR, Kung F, Henry P, McIntyre OR, Kaan SK (1981) Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B. Blood 58:1203
14. Stone RM, Berg TB, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA, for the Cancer and Leukemia Group B (1995) Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 332:1671
15. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Bacerzak SP, Bickers JN, Hynes HE, Welborn JL, Simon SR, Grever M (1996) A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study. Blood 88:2841